LI-RADS Classification and Outcomes of Hepatocellular Carcinoma Treated With Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation

Yuji Tachibana; Ryo Takaji; Miyuki Maruno; Koichi Honda; Mizuki Endo; Kazunari Murakami; Yoshiki Asayama

doi:10.21873/cdp.10130

LI-RADS Classification and Outcomes of Hepatocellular Carcinoma Treated With Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation

Cancer Diagn Progn. 2022 Jul 3;2(4):471-481. doi: 10.21873/cdp.10130. eCollection 2022 Jul-Aug.

Authors

Yuji Tachibana¹, Ryo Takaji², Miyuki Maruno², Koichi Honda³, Mizuki Endo⁴, Kazunari Murakami³, Yoshiki Asayama²

Affiliations

¹ Graduate School of Medicine, Oita University, Oita, Japan.
² Department of Radiology, Faculty of Medicine, Oita University, Oita, Japan.
³ Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
⁴ Medical Safety Management Center, Oita University Hospital, Oita, Japan.

Abstract

Aim: The aim of this study was to clarify the usefulness of the Liver Imaging Reporting and Data System (LI-RADS) for predicting a patient's prognosis after transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (TACE-RFA) for hepatocellular carcinoma (HCC) of Barcelona-Clinic Liver Cancer (BCLC) stage 0 or A.

Patients and methods: We retrospectively analyzed cases of patients with HCC who underwent TACE-RFA (Jan 2005 to Dec 2015). Nodules were categorized based on their LI-RADS v2018 core. The LI-RADS category was assigned to each nodule using dynamic contrast-enhanced computed tomography. LR-3, LR-4 and LR-5 nodules were extracted. The overall (OS) and recurrence-free (RFS) survival was assessed among patients with BCLC 0 and BCLC A disease.

Results: Of the 64 nodules extracted, 22 were LR-3 or -4 (mean±standard deviation=14.8±6.7 mm) and 42 were LR-5 (17.1±6.9 mm). Regarding OS, there was no significant difference between those with LR-3 or -4 and LR-5 (p=0.278). In terms of RFS, there was a significant difference between those with LR-3 or -4 and those with LR-5 (p=0.03). In particular, patients with BCLC A with LR-5 nodules had significantly poorer RFS than those with LR-3 or -4 (p=0.016) nodules.

Conclusion: For patients with BCLC A, LR-3 or -4 nodules are associated with a better prognosis than LR-5 nodules.

Keywords: Barcelona-Clinic Liver Cancer stage; Hepatocellular carcinoma; Liver Imaging Reporting and Data System; radiofrequency ablation; transcatheter arterial chemoembolization.